- Report
- August 2025
- 189 Pages
Global
From €3334EUR$3,545USD£2,781GBP
€3705EUR$3,939USD£3,090GBP
- Report
- May 2024
- 200 Pages
Global
From €3903EUR$4,150USD£3,256GBP
- Report
- February 2024
- 185 Pages
North America
From €3245EUR$3,450USD£2,707GBP
- Report
- October 2023
- 146 Pages
Africa, Middle East
From €3245EUR$3,450USD£2,707GBP
- Report
- October 2023
- 145 Pages
From €3245EUR$3,450USD£2,707GBP
- Report
- July 2023
- 198 Pages
Europe
From €3245EUR$3,450USD£2,707GBP
- Report
- June 2023
- 184 Pages
Asia Pacific
From €3245EUR$3,450USD£2,707GBP
- Report
- March 2023
- 185 Pages
Global
From €4185EUR$4,450USD£3,491GBP
- Report
- October 2025
- 150 Pages
Global
From €4561EUR$4,850USD£3,805GBP
- Report
- September 2025
- 94 Pages
Global
From €3500EUR$3,986USD£3,022GBP
- Report
- November 2026
- 50 Pages
Global
From €2492EUR$2,650USD£2,079GBP
Yttrium-90 is a radioactive isotope used in Nuclear Medicine and Radiopharmacology. It is used in the treatment of cancer, as well as other diseases, and is produced in nuclear reactors. Yttrium-90 is used in a variety of medical applications, including targeted radiotherapy, radioembolization, and radioimmunotherapy. It is also used in the diagnosis of certain diseases, such as liver cancer.
Yttrium-90 is produced in a variety of forms, including microspheres, nanospheres, and liquid formulations. It is also available in a variety of formulations, including capsules, tablets, and injectables.
The Yttrium-90 market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Nordion, Eckert & Ziegler, IBA Molecular, and Advanced Accelerator Applications. Show Less Read more